Peer-reviewed veterinary case report
Imatinib versus vinblastine and prednisone for treating dog mast cell
By Thais Rodrigues Macedo et al.·Published in Cells·2022·Department of Surgery, School of Veterinary Medicine and Animal Science, University of São Paulo, São Paulo 05508-010, Brazil, CH·View original on DOAJ →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Imatinib Mesylate for the Treatment of Canine Mast Cell Tumors: Assessment of the Response and Adverse Events in Comparison with the Conventional Therapy with Vinblastine and Prednisone
- Species:
- dog
Plain-English summary
A group of dogs with mast cell tumors (a type of skin cancer) was treated with either imatinib mesylate or a combination of vinblastine and prednisone. The dogs receiving imatinib showed a significantly better response to treatment, with 30.79% of them improving compared to just 9.09% in the other group. Additionally, the side effects in the imatinib group were mild, while the conventional treatment caused more severe reactions. Overall, imatinib mesylate appears to be a promising option for treating low-grade mast cell tumors in dogs, with fewer side effects.
People also search for: dog mast cell tumor treatment · imatinib for dogs · vinblastine side effects in dogs
Abstract
Mast cell tumors (MCTs) are common neoplasms in dogs, and treatments for these diseases include surgery, polychemotherapy and targeted therapy with tyrosine kinase inhibitors. This study aimed to evaluate the response and the adverse events of treatment with imatinib mesylate (IM) compared to conventional therapy using vinblastine and prednisolone (VP) in canine cutaneous MCTs. Twenty-four dogs were included in the study; 13 animals were treated with IM and 11 with VP. Tumor tissue samples were submitted for histological diagnosis, grading and KIT immunostaining. The response to treatment was assessed by tomographic measurements according to VCOG criteria. Adverse events were classified according to VCOG-CTCAE criteria. The IM and VP groups had dogs with similar breeds, gender, ages, MCT localization, WHO stages and lymph node metastasis profiles. Most MCTs were grade 2/low and had KIT- patterns 2 and 3. The objective response rate (ORR) was significantly higher (30.79%) in the IM group then in VP group (9.09%). Adverse events (AE) in IM group were all grade 1, significantly different from VP. In conclusion, IM presented better ORR and less severe adverse events when compared to VP, representing a suitable option for the treatment of low-grade canine MCTs.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on DOAJ: https://doi.org/10.3390/cells11030571